Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126409201 | 12640920 | 1 | I | 20151027 | 20160804 | 20160810 | 20160810 | EXP | CH-SM-2016-06089 | CH-GLAXOSMITHKLINE-CH2016113275 | GLAXOSMITHKLINE | 36.77 | YR | F | Y | 69.00000 | KG | 20160810 | MD | CH | CH |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126409201 | 12640920 | 1 | SS | CYCLOPHOSPHAMIDE. | CYCLOPHOSPHAMIDE | 1 | Intravenous drip | 600 MG/M2, UNK | 0 | 600 | MG/M**2 | ||||||||
126409201 | 12640920 | 2 | SS | PACLITAXEL. | PACLITAXEL | 1 | Intravenous drip | 80 MG/M2, UNK | 0 | 80 | MG/M**2 | ||||||||
126409201 | 12640920 | 3 | PS | ZANTAC | RANITIDINE HYDROCHLORIDE | 1 | Intravenous bolus | 50 MG, QD | 18703 | 50 | MG | QD | |||||||
126409201 | 12640920 | 4 | SS | Tavegyl | CLEMASTINE FUMARATE | 1 | Intravenous drip | 2 MG, QD | 0 | 2 | MG | QD | |||||||
126409201 | 12640920 | 5 | SS | EMEND | APREPITANT | 1 | Oral | 125 MG, UNK | 0 | 125 | MG | ||||||||
126409201 | 12640920 | 6 | SS | EPIRUBICIN | EPIRUBICIN | 1 | Oral | 90 MG/M2, UNK | 0 | 90 | MG/M**2 | ||||||||
126409201 | 12640920 | 7 | SS | MEPHAMESON | DEXAMETHASONE | 1 | Intravenous drip | 8 MG, QD | 0 | 8 | MG | QD | |||||||
126409201 | 12640920 | 8 | SS | SOLU-MEDROL | METHYLPREDNISOLONE SODIUM SUCCINATE | 1 | Intravenous bolus | 62.5 MG, UNK | 0 | 62.5 | MG | ||||||||
126409201 | 12640920 | 9 | SS | ALOXI | PALONOSETRON HYDROCHLORIDE | 1 | Intravenous bolus | 0.25 MG, UNK | 0 | .25 | MG | ||||||||
126409201 | 12640920 | 10 | SS | ZOFRAN | ONDANSETRON HYDROCHLORIDE | 1 | Intravenous drip | 8 MG, QD | 0 | 8 | MG | QD |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
126409201 | 12640920 | 1 | Breast cancer |
126409201 | 12640920 | 2 | Breast cancer |
126409201 | 12640920 | 3 | Drug reaction with eosinophilia and systemic symptoms |
126409201 | 12640920 | 4 | Drug reaction with eosinophilia and systemic symptoms |
126409201 | 12640920 | 5 | Prophylaxis of nausea and vomiting |
126409201 | 12640920 | 6 | Breast cancer |
126409201 | 12640920 | 7 | Drug reaction with eosinophilia and systemic symptoms |
126409201 | 12640920 | 8 | Prophylaxis of nausea and vomiting |
126409201 | 12640920 | 9 | Prophylaxis of nausea and vomiting |
126409201 | 12640920 | 10 | Drug reaction with eosinophilia and systemic symptoms |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
126409201 | 12640920 | OT |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
126409201 | 12640920 | Exposure during pregnancy | |
126409201 | 12640920 | Live birth | |
126409201 | 12640920 | Premature baby |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
126409201 | 12640920 | 1 | 20151027 | 20151228 | 0 | |
126409201 | 12640920 | 2 | 20160121 | 20160121 | 0 | |
126409201 | 12640920 | 3 | 20160121 | 20160121 | 0 | |
126409201 | 12640920 | 4 | 20160121 | 20160121 | 0 | |
126409201 | 12640920 | 5 | 20151027 | 20151118 | 0 | |
126409201 | 12640920 | 6 | 20151027 | 20151228 | 0 | |
126409201 | 12640920 | 7 | 20160121 | 20160121 | 0 | |
126409201 | 12640920 | 8 | 20151027 | 20151228 | 0 | |
126409201 | 12640920 | 9 | 20151027 | 20151228 | 0 | |
126409201 | 12640920 | 10 | 20160121 | 20160121 | 0 |